Contact: to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Elan (Ireland) Latest News, Events and Discoveries
Elan, a drug based firm was founded in the year 1969 in Ireland. The firm develops products for individuals suffering from life threatening diseases. It works very hard to produce innovative therapies and makes sure that it reaches the population with unmet medical needs. The firm is also conducting research trials in the area of auto immune diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel diseases. The firm is also extending its research to produce drugs that would ease and treat physiological and neuropathic pain.

Elan started off as a private ltd. company and went on to become a public ltd company in the year 1984.

Popular biotech products
Elan is dedicated to produce and develop drugs for treating diseases like Alzheimer’s and bipolar disorders. The products developed for treating this disease condition is ELND005 which is basically a β amyloid anti – aggregation agent. The effectiveness of this molecule was studied in patients with Alzheimer’s and bipolar disorder I and its efficacy proved. The drug was also tested on patients with Down syndrome.
It has been recommended that individuals with Alzheimer’s disease should take drug in dosage of 250mg daily twice.

Tysabri is a drug that is marketed by two firms. Earlier it was named as antregan which is indicated in conditions of multiple sclerosis and Crohn’s disease.

Latest discoveries
Amongst the various discoveries, the firm has made several notable contributions in the field of neurology for treating patients with neurological disorders. Of the several discoveries, of late the firm is working to develop a vaccine called ACC-001 for Alzheimer’s disease. It has also developed AAB-003 monoclonal antibody as a part of Alzheimer’s immunotherapy program.

Elan Corporation is also conducting extensive research to study the Parkinson’s disease. It is in the process of developing therapeutic drugs for this disease. The firm together with Wyeth is conducting Phase III clinical trials for the drug bapineuzumab.

Recent company takeovers
Elan Corporation understands and recognizes the importance of collaborations and affiliations with several firms. Partnerships not only help in widening the business prospects but also helps in conducting quality research.

In the year 2013, the firm decided to give away the right to sell the drug Tysabri to Biogen Idec. The deal was worth about $ 3.25 billion.
Elan has also joined hands with Wyath for conducting the phase III clinical trials for bapineuzumab. However, the results for this drug for the previous two phases were non – conclusive, but Elan is hopeful that this drug can be effective for treatment of Alzheimer’s disease.

Recent corporate news
Elan Corporation is traded in the shares of New York as well as Irish stock exchanges. The firm holds about 49.9% equity interest in Janssen Alzheimer Immunotherapy and will also receive 49.9% share of profits. The firm is also entitled to receive royalty payments for commercialization of AIP products.
Elan also receives royalty on in – market sales of the drug Tysabri. In the year 2010, the firm was fined $203m for marketing of epilepsy drugs.

Work culture
The work culture at Elan Corporation is very dynamic and positive. The people of Elan believe in science and work with the faith, that with their knowledge and hard work they can certainly make a difference in the lives of patients living with several disease conditions.
Elan is forever on the lookout for individuals who are vibrant and full of energy. Individuals who are ready to undertake any challenges for creating a better and disease free living world. The working environment of this firm is very unique and offers its employees an opportunity to grow and achieve the impossible.

The firm is a good paymaster and also rewards its employees for their outstanding performance. Not just this, the firm also has special provisions for its employees such as life insurance, health insurance that covers both dental and vision related issues, disability benefits, assistance for educational purposes, flexible spending accounts, annual paid time off, employee stock purchase plan, referral incentives and retirement plans.

Interesting events
Elan Corporation with its constant development and innovations is constantly in the news. The current year has indeed been an eventful year for this firm. Following is a list of interesting events that have taken place.
• In the month of September, the firm announced the initiation of dosing of Scyllo inositol in patients with Down syndrome.
• The firm reported the second quarter of financial results.
• The firm was awarded injunction against the Royalty Pharma.
• The firm entered into a partnership with Theravance Royalty participation agreement worth $ 1 billion.
• The firm also provided update on the drug Tysabri transaction and $1 bn shares.
• Earlier in this month, the firm along with Biogen Idec submitted applications for use of Tysabri in Anti – JCV antibody negative patients with multiple sclerosis.
In addition to these, the firm also took active participation in the following events:
• Elan Perrigo Joint Conference Call.
• Q2 2013 Elan Corporation, PLC earnings conference call

Recent Openings:
At present there are no recent openings.
Like Post Reply
Bapineuzumab and Alzheimer Disease

In September 2009, JANSSEN Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, acquired Elan’s Alzheimer's Immunotherapy Program (AIP), including Bapineuzumab. Bapineuzumab is an anti- Amyloid-beta (Aß) monoclonal antibody targeting the N-terminal region of the Aß protein. It was developed as a potential Alzheimers’ therapy as Aß protein aggregation contributes to the amyloid plaques on the brain which are characteristic of Alzheimer Disease (AD). It was considered to be a potentially useful antibody for use in passive immunotherapy in AD according to the amyloid cascade hypothesis.

However, Bapineuzumab has not fulfilled its promise as a potential AD therapy. Phase II clinical trials on patients with mild to moderate AD suggested that Bapineuzumab reduced CSF T-tau and P-tau proteins and reduced Aß burden in the brain. However, safety concerns were also raised, for example incidence of reversible vasogenic edema, particularly for higher doses of Bapineuzumab and in APOE epsilon4 carriers. Retrospective analysis also suggested increased risk of amyloid-related imaging abnormalities (ARIA) in APOE ɛ4 carriers and with high bapineuzumab dose, although with varying clinical associations. Furthermore, phase III trials did not convincingly show an impact of bapineuzumab on cognitive function. Johnson & Johnson ended Phase II testing of subcutaneous Bapineuzumab in July 2013 while phase III development of bapineuzumab IV in mild to moderate Alzheimer's was already discontinued in August 2012. An AD vaccine (ACC-001) is still being developed.

Current research suggests that moving from monoclonal antibodies such as Bapineuzumab towards intravenous polyclonal immunoglobulins may present a way forward for passive anti-amyloid immunotherapy in AD. Soluble Aß oligomers may also present a promising target. The international EU/US/CTAD Task Force have made various suggestions that could help ensure success in future clinical trials of AD drugs, including larger phase II studies, evidence of effects on downstream biomarkers before considering phase II tests and most importantly adopting measurement of cognition as the most reliable indicator of benefit.

BARAKOS, J. et al., 2013. MR Imaging Features of Amyloid-Related Imaging Abnormalities. American Society of Neuroradiology.
BLACK, R.S. et al., 2010. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders, 24(2), pp. 198-203
BLENNOW, K. et al., 2012. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Archives of Neurology, 69(8), pp. 1002-1010
GRUNDMAN, M. et al., 2013. 2012: A watershed year for Alzheimer's disease research. The journal of nutrition, health & aging, 17(1), pp. 51-53
HEFTI, F. et al., 2013. The case for soluble Aß oligomers as a drug target in Alzheimer's disease. Trends in pharmacological sciences, 34(5), pp. 261-266
KERCHNER, G.A. and BOXER, A.L., 2010. Bapineuzumab. Expert Opinion On Biological Therapy, 10(7), pp. 1121-1130
MILES, L.A. et al., 2013. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Scientific Reports, 3, pp. 1302-1302
MORETH, J., MAVOUNGOU, C. and SCHINDOWSKI, K., 2013. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immunity & Ageing: I & A, 10(1), pp. 18-18
PANZA, F. et al., 2011. Anti-ß-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Current Alzheimer Research, 8(8), pp. 808-817
RINNE, J.O. et al., 2010. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, 9(4), pp. 363-372
ROHER, A.E. et al., 2013. Bapineuzumab alters aß composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. Plos One, 8(3), pp. e59735-e59735
ROHER, A.E. et al., 2011. Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. Netherlands: IOS Press.
SALLOWAY, S. et al., 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 73(24), pp. 2061-2070
SPERLING, R. et al., 2012. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. England: Lancet Pub. Group.
TAYEB, H.O. et al., 2013. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opinion On Biological Therapy, 13(7), pp. 1075-1084
VELLAS, B. et al., 2013. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimer's & Dementia: The Journal Of The Alzheimer's Association, 9(4), pp. 438-444
ZAGO, W. et al., 2012. Neutralization of soluble, synaptotoxic amyloid ß species by antibodies is epitope specific. The Journal Of Neuroscience: The Official Journal Of The Society For Neuroscience, 32(8), pp. 2696-2702
Like Post Reply

Possibly Related Threads…
Last Post
Replies: 3
Views: 24,031
02-18-2017, 05:29 PM
Last PostAbdul
Replies: 0
Views: 7,488
03-31-2016, 09:06 PM
Last PostHEL Group
Replies: 0
Views: 15,144
07-25-2015, 04:16 AM
Last Postgmshim
Replies: 1
Views: 17,792
03-26-2015, 04:12 PM
Last Postjuston33

Users browsing this thread:
1 Guest(s)

Elan (Ireland) Latest News, Events and Discoveries00